Protease sequences from HIV-1 group M subtypes A???H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide
- 1 July 2000
- journal article
- basic science
- Published by Wolters Kluwer Health in AIDS
- Vol. 14 (11), 1489-1495
- https://doi.org/10.1097/00002030-200007280-00004
Abstract
Background Although numerous mutations that confer resistance to protease inhibitors (PRI) have been mapped for HIV-1 subtype B, little is known about such substitutions for the non-B viruses, which globally cause the most infections. Objectives To determine the prevalence of PRI-associated mutations in PRI-naive individuals worldwide. Design Using the polymerase chain reaction, protease sequences were amplified from 301 individuals infected with HIV-1subtypes A (79), B (95), B’ (19), C (12), D (26), A/E (23), F (26), A/G (11), and H (3) and unclassifiable HIV-1 (7). Amplified DNA was directly sequenced and translated to amino acids to analyze PRI-associated major and accessory mutations. Results Of the 301 sequences, 85% contained at least one codon change giving substitution at 10, 20, 30, 36, 46, 63, 71, 77, or 82 associated with PRI resistance; the frequency of these substitutions was higher among non-B (91%) than B (75%) viruses (P < 0.0005). Of these, 25% carried dual and triple substitutions. Two major drug resistance-conferring mutations, either 20M or 30N, were identified in only three specimens, whereas drug resistance accessory mutations were found in 252 isolates. These mutations gave distinct prevalence patterns for subtype B, 63P (62%) > 77I (19%) > 10I/V/R (6%) = 36I (6%) = 71T/V (6%) > 20R (2%), and non-B strains, 36I (83%) > 63P (17%) > 10I/V/R (13%) > 20R(10%) > 77I (2%), which differed statistically at positions 20, 36, 63, 71, and 77. Conclusions The high prevalence of PRI-associated substitutions represent natural polymorphisms occurring in PRI-naive patients infected with HIV-1 strains of subtypes A−H. The significance of distinct mutation patterns identified for subtype B and non-B strains warrants further clinical evaluation. A global HIV-1 protease database is fundamental for the investigation of novel PRI.Keywords
This publication has 30 references indexed in Scilit:
- Introduction of HIV drug-resistance testing in clinical practiceAIDS, 1999
- Sequence and Drug Susceptibility of Subtype C Protease from Human Immunodeficiency Virus Type 1 Seroconverters in ZimbabweAIDS Research and Human Retroviruses, 1999
- Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence DatabaseNucleic Acids Research, 1999
- Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patientsAIDS, 1998
- HIV-Protease InhibitorsNew England Journal of Medicine, 1998
- Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arraysNature Medicine, 1996
- Natural Variation in HIV-1 Protease, Gag p7 and p6, and Protease Cleavage Sites within Gag/Pol Polyproteins: Amino Acid Substitutions in the Absence of Protease Inhibitors in Mothers and Children Infected by Human Immunodeficiency Virus Type 1Virology, 1996
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and TherapyScience, 1995
- Active human immunodeficiency virus protease is required for viral infectivity.Proceedings of the National Academy of Sciences, 1988